Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Sucampo Pharmaceuticals, Inc.    SCMP   US8649091068

 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/08/2014 09/09/2014 09/10/2014 09/11/2014 09/12/2014 Date
6.64(c) 6.67(c) 6.72(c) 6.75(c) 6.61(c) Last
82 171 46 815 41 982 52 181 51 648 Volume
-0.90% +0.45% +0.75% +0.45% -2.07% Change
More quotes
Company
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company which engages in research, discovery, development and commercialization of proprietary drugs based on prostones and other novel drug technologies. Prostones are naturally occurring fatty acid metabolites with unique physiological... 
Surperformance© rating of Sucampo Pharmaceuticals, I
Trading Rating : Investor Rating :
More about the company
Chart SUCAMPO PHARMACEUTICALS, I
Duration : Period :
Sucampo Pharmaceuticals, I Technical Analysis Chart | SCMP | US8649091068 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 103 M
EBIT 2014 13,2 M
Net income 2014 6,38 M
Debt 2014 -
Yield 2014 -
Sales 2015 131 M
EBIT 2015 32,0 M
Net income 2015 21,7 M
Debt 2015 -
Yield 2015 -
PER 2014 45,59
PER 2015 13,63
Capi. / Sales 2014 2,83x
Capi. / Sales 2015 2,23x
Capitalization 293 M
More Financials
Latest news on SUCAMPO PHARMACEUTICALS, I
08/21 SUCAMPO PHARMACEUTICALS : Entry into a Material Definitive Agreement, Terminatio..
08/21 SUCAMPO PHARMACEUTICALS : Announces New Exclusive Global Manufacturing and Suppl..
08/06 SUCAMPO PHARMACEUTICALS : Management's Discussion and Analysis of Financial Cond..
08/05 SUCAMPO PHARMACEUTICALS : Results of Operations and Financial Condition, Regulat..
08/05 Sucampo Reports Second Quarter 2014 Financial Results and Corporate Update
07/23 SUCAMPO PHARMACEUTICALS : Announces Publication of NICE Recommendation for AMITI..
07/22 SUCAMPO PHARMACEUTICALS : Other Events (form 8-K)
07/22 SUCAMPO PHARMACEUTICALS : Announces Second Quarter 2014 Financial Results and Co..
07/07 SUCAMPO PHARMACEUTICALS : Swissmedic Approves AMITIZA(R) (Lubiprostone) for the ..
06/17 SUCAMPO PHARMACEUTICALS : AMITIZA(R) (Lubiprostone) Receives NICE Recommendation
06/12 SUCAMPO PHARMACEUTICALS : Issues Statement Regarding Anesthetic and Analgesic Dr..
06/05 SUCAMPO PHARMACEUTICALS : Regulation FD Disclosure, Financial Statements and Exh..
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Technical analysis
Income Statement Evolution
Sucampo Pharmaceuticals, I : Income Statement Evolution
More Financials
EPS Revisions
Sucampo Pharmaceuticals, I : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF